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Background: Interleukin-6 (IL-6) is released from skeletal muscle during exercise and
systemic IL-6 levels therefore increase acutely in response to a single bout of exercise.
We recently showed that an acute increase in IL-6 delayed gastric emptying rate and
improved postprandial glycemia. Here we investigate whether repeated increases in
IL-6, induced by exercise training, influence gastric emptying rate and moreover if IL-6
is required for exercise-induced adaptations in glycemic control including secretion of
glucagon and glucagon-like peptide-1 (GLP-1).
Methods: A total of 52 abdominally obese non-diabetic men and women were
randomly assigned into four groups performing 12 weeks of endurance exercise or no
exercise with or without IL-6 receptor blockade (tocilizumab). The primary endpoint was
change in gastric emptying rate in response to the intervention and other endpoints
included changes in glycemic control, glucagon, and GLP-1 secretion.
Results: There was no change in gastric emptying rate in any of the four groups
following the intervention and comparing differences in change between groups also
revealed no difference. Postprandial glucose remained unchanged in all groups but
the exercise + tocilizumab group, which improved postprandial glucose in response
to the intervention. The area under the curve for meal-stimulated glucagon, active
and total GLP-1 increased in response to IL-6 receptor blockade, this effect was
independent of exercise.
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Conclusion: Exercise training and long-term IL-6 receptor blockade did not
change gastric emptying rates in obese humans. IL-6 receptor blockade increased
glucagon and GLP-1 secretion and implicate IL-6 in the regulation of the human
alpha and L cells.
Keywords: interleukin-6, gastric emptying, exercise, tocilizumab, glucagon, GLP-1
INTRODUCTION
Gastric emptying is a critical regulator of postprandial glucose
contributing to as much as 35% of peak glucose following a
meal (Horowitz et al., 1993). Postprandial glucose levels are
important for glycated hemoglobin (HbA1c) (Ceriello et al.,
2004) emphasizing the relevance of in-depth understanding of
the physiological regulators of gastric emptying.
Interleukin-6 (IL-6) is a cytokine influencing glucose
homeostasis (Matthews et al., 2010). We recently showed that
acutely increased IL-6, following an IL-6 infusion, delayed gastric
emptying rate and improved postprandial glucose (Lehrskov
et al., 2018). Consistent with these effects, IL-6 receptor blockade
enhanced the rate of gastric emptying after an acute bout of
exercise suggesting that IL-6 regulation of gastric emptying may
be a physiological phenomenon (Lehrskov et al., 2018).
IL-6 is also a myokine released from skeletal muscle in
response to exercise (Pedersen et al., 2001). During exercise,
systemic IL-6 levels increase acutely and return to baseline within
hours (Fischer, 2006). Exercise on a regular basis (training)
is therefore associated with repeated increases in plasma IL-6.
Whether exercise-induced IL-6 plays a role in the metabolic
adaptations to exercise training is unclear. In some ways, IL-6
regulation of glucose metabolism bears resemblances to the
effects of exercise on glucose metabolism. Infusion of IL-6 has
shown beneficial effects of IL-6 on peripheral glucose uptake
(Febbraio et al., 2004; Carey et al., 2006) and insulin stimulated
glucose uptake (Carey et al., 2006). Whether repetitive increases
in IL-6 induced by exercise training changes gastric emptying rate
has not been investigated.
Most studies investigating exercise effects on gastric emptying
have studied the acute effect of a single bout of exercise on gastric
emptying during a post exercise meal (Horner et al., 2015b).
A meta-analysis of these studies revealed a possible effect of
exercise intensity on gastric emptying (Horner et al., 2015b). The
mechanism behind this exercise intensity-dependent regulation
of gastric emptying has not been identified.
The incretin hormone, glucagon-like peptide-1 (GLP-1) is
secreted from the intestinal L cells in response to nutrients;
however, GLP-1 has also been shown to increase during an
acute exercise bout (Martins et al., 2007) and some studies
have demonstrated an increased secretory capacity of the L cell
following an exercise training intervention (Chanoine et al., 2008;
Martins et al., 2010).
IL-6 stimulates GLP-1 secretion from L cells under certain
circumstances in vitro (Ellingsgaard et al., 2011); and in rodents,
exercise-induced GLP-1 was found to be dependent on IL-6
(Ellingsgaard et al., 2011). A link between training-induced
adaptations of the L cell and IL-6 signaling has not been described
in humans. The pancreatic alpha cell has been shown to be
under the influence of IL-6, and in vitro and in vivo studies
have shown that IL-6 stimulates glucagon secretion (Ellingsgaard
et al., 2008; Tweedell et al., 2011; Fernández-Millán et al., 2013;
Chow et al., 2014; Lehrskov et al., 2018). Whether long-term
IL-6 receptor blockade influences glucagon secretion has not
been demonstrated.
To investigate the role of IL-6 in training-induced adaptations
of gastric emptying, glycemic control, and GLP-1 secretion,
abdominally obese inactive individuals performed a 12-week
exercise training intervention or no exercise training (control)
in the presence and absence of the IL-6 receptor blockade
(tocilizumab). We hypothesized that repetitive increases in IL-6
induced by exercise training would decelerate gastric emptying
rate, and moreover that this effect would be abolished in the
presence of IL-6 receptor blockade.
MATERIALS AND METHODS
Study and Participants
This study was a randomized exercise training intervention study
with the overall primary endpoint to investigate the role of IL-6
in exercise training-induced regulation of visceral adipose tissue
mass (Wedell-Neergaard et al., 2018). Data regarding visceral
adipose tissue are published previously (Wedell-Neergaard et al.,
2018). The study was performed between August 2016 and April
2018 at the Centre for Physical Activity Research (CFAS) in
Copenhagen, Denmark. The study was approved by the ethical
committee of the Capital Region of Denmark (H-16018062) and
reported to the Danish Data Protection Agency (2012-58-0004).
The study was registered at ClinicalTrials.gov NCT02901496
and was conducted in accordance with the guidelines for Good
Clinical Practice and the Declaration of Helsinki. All participants
provided written informed consent.
The full study protocol is published (Christensen et al.,
2018). Briefly, participants were eligible if they were physically
inactive (defined as less than 2.5 h of physical activity per
week) (Tremblay et al., 2017) and abdominally obese (waist
to height ratio ≥ 0.5 and/or waist circumference ≥ 88/102 cm
for women/men, respectively) and age > 18 years old. Key
exclusion criteria were diabetes (HbA1c ≥ 48 mmol/mol or
fasting glucose ≥ 7.0 mmol/l), pregnancy or breastfeeding,
ischemic heart disease, infectious or immunosuppressive
disease, treatment with NSAID, treatment with biologic
drugs for rheumatic diseases, systemic prednisolone,
other immunotherapy or health conditions that prevented
participation in the exercise intervention (e.g., severe obesity).
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FIGURE 1 | Flowchart.
Permitted medication should be taken at a stable dose for at least
4 weeks prior to randomization and preferably remain stable
throughout the study period.
Data related to adverse events are published
(Wedell-Neergaard et al., 2018).
Randomization
Eligible participants were block-randomized (1:1:1:1:1) into
five groups as described in the protocol paper (Christensen
et al., 2018). The randomization sequence was generated by
one researcher who did not participate in any clinical study
procedures (KK) and concealed from all other researchers.
The principal study investigators thus remained blinded to the
training modality as well as the infusions (tocilizumab/saline).
The five randomized groups were: no exercise + placebo,
no exercise + tocilizumab, exercise + placebo, exercise +
tocilizumab, or resistance training + placebo as described in
the protocol paper (Christensen et al., 2018), all participants
except those allocated to resistance training were included in the
analyzes of this particular study (Figure 1).
IL-6 Receptor Blockade (Tocilizumab)
The recombinant humanized monoclonal IL-6 receptor antibody
tocilizumab (Roche, Basel, Switzerland) was reconstituted in
saline and a total volume of 100 ml was infused monthly
over 1 h at the maximal recommended dose of 8 mg/ml or a
maximum of 800 mg (RoActemra | European Medicines Agency,
n.d.). European Public Assessment Report for RoActemra. The
concentration of tocilizumab following infusion of 8 mg/kg
tocilizumab ranges from 10 to 183 µg/ml. Complete blockade is
Frontiers in Physiology | www.frontiersin.org 3 October 2019 | Volume 10 | Article 1249
fphys-10-01249 October 3, 2019 Time: 15:49 # 4
Lang Lehrskov et al. Gastric Emptying - Exercise and IL-6 Blockade
achieved at 4 µg/ml (Song and Yoshizaki, 2015). Given the half-
life of tocilizumab of 13 days, it can be anticipated tocilizumab
fully blocked IL-6 actions during the intervention period.
Study Visits and Interventions
Before and after the intervention all participants went through
several study visits including medical screening, blood sampling,
mixed meal tolerance tests (MMTT), Dual X-ray Absorptiometry
(DXA) scans, and maximal oxygen consumption rate (VO2
max) tests. Continuous glucose monitoring (CGM) and diet
registration were performed over a 3-day period before and
after the intervention. The intervention consisted of 12 weeks
of supervised endurance exercise or no exercise combined with
monthly infusion of tocilizumab. Saline was infused as placebo.
Each exercise bout was 45 min high-intensity interval training
and was performed on an ergometer bicycle. The intensity
progressively increased over the 12-week training period. Safety
and compliance were assessed every 4 weeks.
DXA and VO2 Max
Dual X-ray Absorptiometry scans were used to assess changes
in body composition (Lunar Prodigy Advance, GE Medical
systems, Milwaukee, United States). VO2 max was determined
during a bicycle ergometer test (Monark Ltd., Varberg, Sweden).
After a 5 min warm-up at 70 w, the load was increased by
15 w every minute until exhaustion. Ventilation rate, oxygen
uptake and expired carbon dioxide levels as well as heart rate
were measured throughout the duration of the test (Quark b2,
Cosmed, Rome, Italy). A test was valid if the respiratory exchange
ratio > 1.1, a plateau in oxygen intake was reached or the heart
rate was ±10 heartbeats from the estimated maximal heart rate
(Edvardsen et al., 2014). The test result was used to determine
the exercise workload for participants randomized to exercise and
to assess changes in aerobic capacity in all four groups following
the intervention.
CGM, Free-Living Physical Activity, and
Diet Registration
To obtain insight into everyday glycemic control, a continuous
glucose sensor (Enlite, Medtronic, Friedly, MN, United States)
was inserted into the abdominal subcutaneous adipose tissue
of all participants. The sensor was connected to a CGM
monitor (iPro2, Medtronic) and calibrated four times daily
with a glucometer (Contour, Bayer, Basel, Switzerland). The
obtained data were analyzed for mean amplitude glycemic
excursions (MAGE) a marker for glycemic variability (Service
et al., 1970). Self-reported dietary intake was registered over
3 days before and after the intervention. Average daily calorie
intake was calculated using madlog-vita.dk. Free-living physical
activity was assessed using accelerometry (AX3, Newcastle,
United Kingdom), sampling frequency 100 Hz, over 4 days before
and after the intervention (Treuth et al., 2004).
Mixed Meal Tolerance Test
The mixed meal was a 360 mL liquid meal containing 385 kcal.
The energy distribution was 15% fat, 20% protein, and 65%
carbohydrate. The meal contained 1.5 g paracetamol to allow
assessment of gastric emptying rate (Heading et al., 1973). The
meal was ingested over less than 2 min. To measure paracetamol
concentrations and parameters of glycemic control blood samples
were drawn regularly (−10, 0, 15, 30, 60, 90, 120, 150, and
180 min) relative to ingestion of the meal. To ensure that no
acute effects of exercise impacted on the MMTT, exercise was not
allowed 48 h prior to the test.
Blood Samples and Analysis
Baseline blood parameters, safety blood parameters, HbA1c,
glucose, insulin, and paracetamol were measured at the
Department of Clinical Biochemistry, Rigshospitalet,
Copenhagen University Hospital. Plasma levels of total GLP-1
were determined using a radioimmunoassay developed in-house
(codename 390) that is COOH-terminal and therefore measuring
GLP-1 (7-36NH2 as well as the metabolite GLP-1 9-36NH2)
as described previously (Orskov et al., 1994). Plasma levels of
active GLP-1 was assessed with a commercially assay (Alpco,
Salem, NH, United States). Plasma glucagon were measured
using a C-terminal based radioimmunoassay (codename 4305)
as described previously (Wewer Albrechtsen et al., 2014). Inter
and intra assay variations for the GLP-1 and glucagon assays
were less than 15 and 6%, respectively, and the lower limit of
quantification was around 1 pmol/L with a precision of 1 pmol/L
(Wewer Albrechtsen et al., 2015).
Modeling Insulin Sensitivity, Secretion,
and Disposition Index
Whole body insulin sensitivity index was calculated by the
Matsuda and DeFronzo method as follows (Matsuda and
DeFronzo, 1999).
Whole body insulin sensitivity index
= 10000−
√(
mean insulin × mean glucose during MMTT)
× (fasting glucose × fasting insulin)
The insulinogenic index was calculated based on insulin and
glucose levels after the meal load during the MMTT (Phillips
et al., 1994; Wareham et al., 1995):
(Insulin 30 min − fasting insulin)/
(glucose 30 min − fasting glucose)
The oral disposition index was assessed during the first
30 min of the MMTT as Matsuda × the insulinogenic index
(Solomon et al., 2014).
Study Endpoints
The main outcome was change in gastric emptying rate
determined as changes in paracetamol kinetics following
the intervention. Other outcomes included changes in
postprandial plasma levels of glucose, insulin. Moreover,
changes in postprandial plasma levels of glucagon, total and
active GLP-1, as well as changes in whole body insulin sensitivity
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index, insulinogenic index, and the oral disposition index, were
assessed as explorative outcomes. Also changes in HbA1c and
glycemic variability were considered as explorative outcomes.
Statistical Analysis
Results are expressed as mean ± SEM in figures and as
mean ± SD in Table 1. Changes within groups and differences
in change between groups are expressed as mean (95% CI).
The level of significance was set at p < 0.05. Statistical
analyses were performed using GraphPad Prism version 7.02
(GraphPad Software, La Jolla, CA, United States). Within-group
differences in plasma concentrations of paracetamol, glucose,
insulin, glucagon, total GLP-1, and active GLP-1 were determined
using the two-way repeated-measure analysis of variance (RM-
ANOVA). Within-group differences in AUC were analyzed
using Student’s paired t-test and differences in change between
groups were assessed using the one-way ANOVA and Student’s
unpaired t-test.
RESULTS
Study Participants
We enrolled 56 participants in the study. Due to protocol
violations four participants were excluded from the data
analysis. The remaining 52 participants were randomized to
no exercise + placebo (n = 12), no exercise + tocilizumab
(n = 13), exercise+ placebo (n = 14), and exercise+ tocilizumab
(n = 13) and included in the per protocol analysis (Figure 1).
In the CGM analysis another five participants were excluded
due to incomplete availability of data. Data from the remaining
47 participants, distributed as follows: no exercise + placebo
(n = 11), no exercise + tocilizumab (n = 12), exercise + placebo
(n = 11), and exercise + tocilizumab (n = 13) were included in
the CGM analysis. Participant characteristics and intervention-
induced changes are shown in Table 1.
Data in Table 1 are published (Wedell-Neergaard et al.,
2018) except for the changes in HbA1c, glycemic variability and
parameters of postprandial glycemic control.
VO2 Max, Training Compliance, Body
Weight, Free-Living Physical Activity, and
Dietary Intake
As anticipated, VO2 max increased in the exercise + placebo
group and in the exercise + tocilizumab group. All participants
in the two training groups complied with the minimum of 29
training sessions, and compliance was similar in the two groups.
Body weight remained unchanged in all groups following the
intervention (Table 1), and there were no differences in free-
living physical activity and dietary intake between the groups.
All data described in this section can be found in our previously
published paper (Wedell-Neergaard et al., 2018).
Circulating Levels of IL-6
As expected, baseline plasma levels of IL-6 increased in
response to tocilizumab (Zhang et al., 2017). Exercise training
for 12 weeks had no effect on baseline IL-6 levels. These
TABLE 1 | Participant characteristics and intervention-induced changes within groups.
No exercise + placebo No exercise + tocilizumab Exercise + placebo Exercise + tocilizumab
Before After Before After Before After Before After
n (male/female) 12 (1/11) 13 (5/8) 14 (3/11) 13 (3/10)
Age (years) 48 (12) 44 (12) 39 (13) 44 (12)
Body composition
Body mass (kg) 95.4 (19.8) 96.0 (19.7) 98.8 (16.9) 99.5 (16.9) 92.4 (13.5) 91.8 (13.6) 95.5 (14.5) 96.4 (15.3)
Lipids (mmol/l)
Total cholesterol 5.1 (0.8) 5.2 (1.0) 5.1 (1.0) 5.6 (1.0) 4.8 (0.9) 4.7 (0.9) 4.8 (0.7) 5.2∗ (0.6)
HDL-cholesterol 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.3 (0.4) 1.4 (0.3) 1.4 (0.3) 1.4 (0.3) 1.5 (0.4)
LDL-cholesterol 3.3 (0.8) 3.4 (0.7) 3.3 (0.9) 3.6∗ (0.9) 3.1 (0.6) 3.0 (0.7) 3.1 (0.7) 3.3 (0.5)
Blood pressure (mmHg)
Systolic 123 (20) 124 (7) 126 (18) 128 (16) 128 (21) 127 (14) 134 (20) 133 (18)
Diastolic 84 (9) 85 (6) 86 (13) 82 (16) 87 (10) 83 (10) 89 (9) 85 (10)
Glycemic control
HbA1c (%) 6.2 (0.6) 6.2 (0.4) 6.3 (0.4) 6.2 (0.4) 5.8 (0.4) 5.9∗ (0.4) 5.8 (0.4) 5.8 (0.4)
HbA1c (mmol/mol) 36.5 (3.8) 36.7 (3.0) 37.2 (2.7) 36.8 (2.9) 33.6 (3.0) 35.0∗ (2.6) 34.0 (3.0) 34.0 (2.6)
Fasting glucose (mmol/l) 5.0 (0.5) 5.1 (0.5) 5.3 (0.9) 5.4 (0.8) 5.1 (0.5) 5.3 (0.7) 5.0 (0.5) 5.0 (0.4)
Fasting insulin (pmol/l) 100 (40) 116 (82) 92 (58) 96 (51) 111 (78) 94 (52) 88 (55) 92 (56)
Glycemic variability, MAGE (CGM) 2.1 (1.1) 1.8 (0.7) 1.9 (0.4) 1.6 (0.5) 1.8 (0.6) 1.4 (0.6) 1.5 (0.4) 1.4 (0.3)
Postprandial glycemic control
Matsuda (MMTT) 3.0 (1.0) 3.3 (1.4) 4.7 (2.8) 4.6 (2.9) 3.4 (1.4) 3.9 (1.9) 3.8 (2.5) 4.5 (2.7)
Insulin secretion index (MMTT) 353 (282) 474 (400) 333 (178) 522 (738) 431 (191) 390 (126) 485 (483) 574 (365)
Oral disposition index (MMTT) 1031 (959) 1498 (1429) 1232 (632) 1846 (2184) 1502 (1040) 1477 (719) 1453 (922) 2093∗ (865)
Data are presented as mean (SD) except from sex. ∗p < 0.05 determined by Student’s paired t-test comparing intervention-induced changes within groups.
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FIGURE 2 | Paracetamol and glucose. (A–D) Plasma paracetamol concentrations during a MMTT (left) and paracetamol AUC 0–60 min (right) before and after (A)
no exercise + placebo, (B) no exercise + tocilizumab, (C) exercise + placebo, and (D) exercise + tocilizumab. (E–H) Plasma glucose concentrations during a MMTT
(left) and blood glucose AUC before and after (E) no exercise + placebo, (F) no exercise + tocilizumab, (G) exercise + placebo, and (H) exercise + tocilizumab.
Tocilizumab is an IL-6 receptor antibody. Data represent mean ± SEM. ∗p < 0.05 using Student’s paired t-test (right).
data are previously reported (Wedell-Neergaard et al., 2018).
IL-6 increased significantly in response to an acute exercise bout
in the exercise + placebo group from 0.77 pg/ml (SD: 0.27)
to 1.14 pg/ml (SD: 0.39) and from 10.23 pg/ml (SD: 5.25) to
11.33 pg/ml (SD: 5.18) in the exercise+ tocilizumab group.
Gastric Emptying
In contrast to our hypothesis there was no effect of exercise
training, IL-6 receptor blockade, or the combination of the two,
on the appearance of paracetamol into the circulation (Figure 2).
Time to appearance, rate of appearance (Figure 2) and area under
the curve (0–60 min) (Figure 2 and Table 2) remained unchanged
in all four groups following the intervention and there was no
difference in change between groups (Table 2). Hence, exercise
training and long-term IL-6 receptor blockade did not affect
gastric emptying in the present study.
Glycemic Control
Postprandial glucose remained generally unaffected by training
and IL-6 receptor blockade (Figure 2 and Table 2), however, in
the exercise + tocilizumab group glucose AUC was significantly
reduced following the intervention (Figure 2). Comparing
differences in change in glucose AUC between groups showed no
difference (Table 2).
The average glucose concentration, assessed by HbA1c,
revealed only small and mostly non-significant changes following
the intervention (Table 1). Consistent with the overall subtle
changes in glycemic control, assessment of glycemic variability,
determined as the MAGE, did not change in response to
any of the interventions (Table 1). Fasting plasma glucose
levels were within the normal range and less than 5.4 mM at
baseline and remained unchanged in all groups following the
intervention (Table 1).
Insulin, Glucagon, and GLP-1
To further elaborate on the adaptations related to glycemic
control we assessed changes in plasma insulin, glucagon and
GLP-1. Plasma levels of fasting and meal-stimulated insulin
remained unchanged following the intervention (Tables 1, 2,
and Figure 3). Modeling insulin sensitivity and insulin secretion
using the Matsuda (Matsuda and DeFronzo, 1999) and
insulinogenic index (Phillips et al., 1994; Wareham et al., 1995)
also revealed no effect of the interventions (Table 1). In line
with reduced postprandial glucose in the exercise + tocilizumab
group, the oral disposition index increased in this group
following the intervention (Table 1), however, comparing
the changes in disposition index between groups showed no
significant difference in change (Table 2).
Despite vague changes in glycemia and no changes in
insulin secretion, a significant stimulatory effect of IL-6 receptor
blockade on meal-induced glucagon secretion (AUC) was
observed in both groups receiving tocilizumab (Figure 3).
Comparing the changes in glucagon secretion between groups
revealed no significant difference in change (Table 2).
The AUC for total and active GLP-1 increased in response
to tocilizumab independently of exercise (Figure 4). Comparing
changes in active and total GLP-1 between groups mostly revealed
no significant difference in change (Table 2).
DISCUSSION
Given that we previously observed a delay in gastric emptying
following an acute increase in IL-6 (Lehrskov et al., 2018) we
hypothesized that repetitive increases of IL-6, induced by exercise
training, would also delay gastric emptying, but in contrast
to our hypothesis exercise training had no effect on gastric
emptying in this study. Our knowledge about the long-term
effects of exercise training on gastric emptying is primarily
based on cross-sectional data which suggests increased gastric
emptying rate in trained individuals (Horner et al., 2011, 2015a).
Studies investigating the effect of a single bout of exercise
on gastric emptying during an immediate post exercise meal
have demonstrated a role for exercise intensity, where increased
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TABLE 2 | Intervention-induced changes during a mixed meal tolerance test within and between groups.
No exercise +
placebo
No exercise +
tocilizumab
Exercise +
placebo
Exercise +
tocilizumab
No exercise +
placebo vs. No
exercise +
tocilizumab
No exercise +
placebo vs.
Exercise +
placebo
No exercise +
placebo vs.
Exercise +
Tocilizumab
Exercise + placebo
vs. Exercise +
Tocilizumab
Paracetamol (0–60 min) 0.3
(−0.2 to 0.8)
0.1
(−0.2 to 0.4)
0.2
(−0.1 to 0.6)
0.2
(−0.2 to 0.7)
−0.2
(−0.8 to 0.4)
0.1
(−0.5 to 0.7)
0.1
(−0.6 to 0.7)
0.0
(−0.5 to 0.5)
Blood glucose −36.0
(−136.0 to 64.1)
−55.8
(−132.7 to21.1)
−19.3
(−84.6 to 46.0)
−62.3
(−124.0 to −0.6)
−19.8
(−137.8 to 98.2)
16.8
(−931 to 126.6)
−26.3
(−135.2 to 82.7)
−43.0
(−128.7 to 42.6)
Insulin 5443
(−14128 to 25013)
−1908
(−16195 to 12380)
−7166
(−20577 to 6242)
−10637
(−26567 to 5293)
−7351
(−29960 to 15259)
12608
(−9285 to 34502)
−16080
(−39741 to 7581)
−3471
(−23130 to 16187)
Glucagon 112.5
(−70.0 to 295.0)
168.8
(17.4 to 320.3)
61.8
(−113.5 to 237.0)
211.8
(28.8 to 394.9)
56.4
(−164.8 to 277.6)
−50.7
(−292.4 to 191.1)
99.4
(−146.2 to 345.0)
150.1
(−90.5 to 390.6)
Total GLP-1 78.2
(−355.5 to 511.9)
333.5
(73.1 to 594.0)
−28
(−308.2 to 252.2)
349
(34.1 to 664.0)
255.4
(−202.8 to 713.5)
−106.2
(−573.5 to 361.1)
270
(−22.8 to 764.5)
377
(21.9 to 775.9)
Active GLP-1 32.0
(−99.5 to 163.4)
448.0
(49.4 to 846.7)
113.8
(−213.9 to 441.4)
412.1
(−23.88 to 848.2)
416.1∗
(20.5 to 811.6)
81.8
(−275.8 to 493.4)
380.2
(−48.9 to 809.3)
298.4
(−208.8 to 805.6)
Matsuda (MMTT) 0.3
(−0.5 to 1.0)
−0.1
(−1.4 to 1.1)
0.6
(−0.2 to 1.3)
0.8
(−0.3 to 2.0)
−0.4
(−1.7 to 0.9)
−0.3
(−1.3 to 0.7)
0.6
(−0.7 to 1.9)
0.3
(−1.0 to 1.5)
Insulin secretion index (MMTT) 121.2
(−33.0 to 275.3)
189.5
(−233.7 to 612.6)
−40.8
(−151.4 to 69.7)
89.4
(−50.8 to 229.5)
68.3
(−356.0 to 492.7)
162.0
(−13.8 to 337.7)
−31.8
(−228.1 to 164.5)
130.2
(−36.5 to 296.9)
Oral disposition index (MMTT) 467.0
(−304.6 to 1239)
631.7
(−653.2 to 1881)
−24.8
(−648.4 to 598.8)
640.4
(120.1 to 1161)
146.7
(−1251 to 1545)
491.8
(−436.7 to 1420)
173.4
(−703.5 to 1050)
665.3
(−121.6 to 1452)
Data are presented as mean change (95% CI) in AUC. ∗p < 0.05 determined by one-way ANOVA and Student’s unpaired t-test comparing differences in change between groups. Tocilizumab is an IL-6 receptor antibody.
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FIGURE 3 | Insulin and glucagon. (A–D) Plasma insulin concentrations during a mixed meal tolerance tests (MMTT) (left) and insulin AUC (right) before and after (A)
no exercise + placebo, (B) no exercise + tocilizumab, (C) exercise + placebo, and (D) exercise + tocilizumab. (E–H) Plasma glucagon concentrations during a MMTT
(left) and glucagon AUC (right) before and after (E) no exercise + placebo, (F) no exercise + tocilizumab, (G) exercise + placebo, and (H) exercise + tocilizumab.
Tocilizumab is an IL-6 receptor antibody. Data represent mean ± SEM. ∗p < 0.05 using Student’s paired t-test (right).
FIGURE 4 | Total and active GLP-1. (A–D) Plasma concentrations of total GLP-1 during a MMTT (left) and total GLP-1 AUC (right) before and after (A) no
exercise + placebo, (B) no exercise + tocilizumab, (C) exercise + placebo, and (D) exercise + tocilizumab. (E–H) Plasma concentrations of active GLP-1 during a
MMTT (left) and active GLP-1 AUC (right) before and after (E) no exercise + placebo, (F) no exercise + tocilizumab, (G) exercise + placebo, and (H)
exercise + tocilizumab. Tocilizumab is an IL-6 receptor antibody. Data represent mean ± SEM. ∗p < 0.05 using Student’s paired t-test (right).
exercise intensity is related to increased gastric emptying rate
(Horner et al., 2015b). Nevertheless, our data showed no effect
of a 12-week exercise-training period on gastric emptying in
physically inactive and abdominally obese people. Whether the
absence of an effect is related to exercise intensity or merely
reflects that exercise training does not change gastric emptying
remains unclear.
Gastric emptying also remained unchanged following long-
term IL-6 receptor blockade. We have however, previously
observed that the same dose of IL-6 receptor blockade increased
gastric emptying during a post exercise meal (Lehrskov et al.,
2018) suggesting that exercise-induced IL-6 delays gastric
emptying. In the present study gastric emptying was assessed
when IL-6 levels were at baseline and it is possible that
tocilizumab regulates gastric emptying only when IL-6 levels
are elevated, such as following an exercise bout. Given the
pharmacokinetic profile of tocilizumab, we can anticipate that the
IL-6 receptor blockade was complete during the post intervention
assessments (Song and Yoshizaki, 2015). Increased plasma
levels of IL-6 and reduced CRP levels support this. Training-
induced adaptations of glycemic control were surprisingly
mild, however, given that participants were normoglycemic
at baseline prior to the training intervention the shortfall of
improvements may be a reflection of a poor potential for
change. One of the early adaptations to training is improved
insulin sensitivity (Dela et al., 1992; Kirwan et al., 2009), yet
modeling insulin sensitivity using the Matsuda index revealed
no effect of training alone. Combining exercise training and
IL-6 receptor blockade significantly reduced postprandial glucose
excursions, which combined with no change in insulin resulted
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in a tendency toward improved Matsuda index and improved
disposition index. Such an effect of long-term IL-6 blockade
is in contrast to the insulin sensitizing effect observed in
response to an infusion of IL-6 (Carey et al., 2006) and
suggest that the improved insulin sensitivity may be secondary
to IL-6 blockade.
That IL-6 receptor blockade increased glucagon secretion
is quite contradictory to studies in rodent and human alpha
cells (Ellingsgaard et al., 2008; Fernández-Millán et al., 2013)
and to in vivo studies in rodents (Tweedell et al., 2011; Chow
et al., 2014) and humans (Lehrskov et al., 2018) which all have
demonstrated increased glucagon secretion in response to IL-6.
However, while most of these studies evaluated the acute effect
of increased IL-6, the present study investigated the consequence
of long-term IL-6 receptor blockade. Thus, the stimulatory
effect of tocilizumab on glucagon secretion may not reflect the
inhibition of a direct effect of IL-6 on the alpha cell, but rather
secondary adaptations of IL-6 receptor blockade. Participants
receiving tocilizumab increased visceral adipose tissue mass
(Wedell-Neergaard et al., 2018) and showed similar trends for
whole body fat mass; therefore on a very speculative note, the
augmented glucagon secretion could be secondary to steatosis
(Suppli et al., 2016).
That both active and total GLP-1 levels were elevated in
response to tocilizumab suggests an effect on the secretion of
GLP-1 (Kuhre et al., 2015) rather than on a DPP-4 mediated
modulation of GLP-1. Increased GLP-1 secretion in response to
IL-6 receptor blockade may seem surprising given the stimulatory
effect of IL-6 on GLP-1 secretion in GLUTag cells (Ellingsgaard
et al., 2011). In humans, however, infusion of IL-6 had no effect
on GLP-1 secretion, whereas infusion of IL-6 receptor blockade
increased GLP-1 (Lehrskov et al., 2018). Thus, it seems that
in humans both acute and long-term IL-6 receptor blockade
increases meal-stimulated GLP-1 secretion. As for glucagon, it
is unclear whether the effect of IL-6 receptor blockade on GLP-
1 secretion is a consequence of inhibiting direct effects of IL-6
on L cells or a result of secondary adaptations to long term
IL-6 blockade. Increased gastric emptying leads to increased
GLP-1 secretion (Holst et al., 2016) which may explain the
increased GLP-1 secretion following acute IL-6 receptor blockade
(Lehrskov et al., 2018), long-term use of IL-6 receptor blockade
did, however, not affect gastric emptying, suggesting that a
different mechanism is involved in the regulation of GLP-1
secretion following long-term IL-6 receptor blockade.
Based on the available data there are no clear implications
of the increased postprandial glucagon and GLP-1 secretion.
Small numerical improvements in postprandial glucose were
observed (significant in the exercise + tocilizumab group), but
these were not associated with changes in insulin secretion or
insulin sensitivity. Of note, both glucagon and GLP-1 levels
remained unchanged in the fasting condition and only increased
in response to the mixed meal, and whether these meal-
associated changes have implications for long-term glycemic
control remains unclear.
In conclusion, our study demonstrated that in obese and
physically inactive people, gastric emptying rates are unaffected
by exercise training and IL-6 receptor blockade. The study also
showed that IL-6 receptor blockade increased glucagon and GLP-
1 secretion and thus implicates IL-6 in the regulation of the
human alpha and L cells.
Limitations
Assessing gastric emptying using the paracetamol approach may
be a limitation as it may not be a sensitive enough method
to detect training-induced changes. Despite that participants
were abdominally obese and physically inactive they were
normoglycemic at baseline, this should be taken into account
when evaluating the data on glycemic control. The power
analysis of the study was based on changes in visceral adipose
tissue mass (Christensen et al., 2018; Wedell-Neergaard et al.,
2018) and not on changes in gastric emptying and glycemic
control, it is therefore possibly that the secondary analyses were
underpowered. Moreover, the sample size was relatively small
and conclusions should be interpreted with caution.
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